

# Gene Therapy of Parkinson’s Disease

Malik A\*, Tabbasum S, Hanif Z and Jabeen N

Department of Bioinformatics and technology, International Islamic University, Islamabad, Pakistan, Postal Code 44000

### Abstract

Parkinson’s is second most common neurological disorder in the world having both sporadic and familial cases. Present Parkinson’s disease genetics taxonomy specifies 18 chromosomal regions that are also called chromosomal locus which are termed PARK. Gene therapy i.e., Use of genes as medicine, is effective and newly discovered treatment of many Central nervous system disorders including Parkinson’s disease. Direct injection was also performed but it does not give suitable results. So, scientist feel need of using different vectors for efficient delivery of genes in Central nervous system. Hence gene therapy of Parkinson’s disease involves use of both viral and non-viral vectors but viral vectors shows efficient results. Frequently used vectors for therapy of Parkinson’s disease are Lentivirus and adeno associated virus. Using these vectors many successful experiments are performed on different animals. Parkin, Glial cell-derived neurotrophic factor (GDNF) and alpha synuclein are some of the successful products for therapy of Parkinson’s disease.

**Keywords:** Parkinson’s disease; Genetics; Gene therapy; Lentivirus

### Introduction

Parkinson’s disease is a very common and widely spread neurological disorder. It is very common among people of all continents and topographical areas [1]. Parkinson’s disease is the second most public neurodegenerative sickness next to Alzheimer’s disease [2]. Symptoms are given in (Table 1).

### Epidemiology and risks

Male is more prone to this disease than females. Men to women ration of Parkinson’s disease is 3:2 [2]. Yearly occurrence rate range is from 8.6 to 19 per 100,000 [2,3]. An occurrence of 1%-2% in the people elder than 60–65 year, or 0.3% in the over-all inhabitants [2,4], with frequency rates fluctuating from 65.6 to 12,500 per 100,000 population [5]. More than 4 million Parkinson’s disease patients were there in the globe in year 2005 [6]. It befalls irregularly below 40 years of age, early onset increasing the possibility that hereditary reasons might be involved [2,7].

### Genetics

Research in Parkinson’s disease shows that many monogenic form of ailments and genetics is involved in the aggregating the risk of Parkinson’s disease. Monogenic forms that are initiated by a single

Symbol	Gene locus	Gene	Inheritance
Park 1	4q21-22	SNCA	Autosomal dominant
Park 2	6q25.2–q27	Parkin	Autosomal recessive
Park 6	1p35–p36	PINK1	Autosomal recessive
Park 7	1p36	DJ-1	Autosomal recessive
Park 8	12q12	LRRK2	Autosomal dominant
Park 9	1p36	ATP13A2	Autosomal recessive
Park 10	1p32	Unknown	Risk factor
Park 14	22q13.1	PLA2G6	Autosomal recessive
Park 15	22q12–q13	FBX07	Autosomal recessive
Park 16	1q32	Unknown	Risk factor

**Table 2:** Parkinson’s disease related loci nominated by PARK [8].

mutation which follows dominant or recessive inherited genetics. They mutually cause 30% of the familial and it was also found in 3% to 5% of the sporadic cases. Present Parkinson’s disease genetics taxonomy specifies 18 chromosomal regions that are also called chromosomal locus which are termed PARK. Confirmed PARK designated gene loci mode of inheritance etc. Are described in (Table 2) [8].

### Gene therapy: An expected treatment of Parkinson’s disease

Gene therapy (use of genes as medicines) is basically used to correct defective genes responsible for genetic disorder [9,10]. Gene medical care is the use of nucleic acids as medication [11]. Thus, as for any drug, its application is going to be primarily restricted to therapeutic uses. Four classes or sorts of factor medical care are defined: (i) corporal factor gene therapy, (ii) corporal genetic enhancement, (iii) germ line factor gene therapy, and (iv) germ line genetic enhancement [12].

About 4,000 sicknesses have been traced which are caused by gene disorders. Modern-day and viable candidates for gene remedy consist

Motor symptoms	Non-motor symptoms
<b>Bradykinesia:</b>	<b>Neuropsychiatric features:</b>
Sluggish drive	Anxiety, panic attacks, Mood disorder, depression, illusion, delusion, dementia
Loss of breadth/rapidity	
Reduction of muscular power (paresis)	<b>Sleep complaints:</b>
Spasticity	Insomnia
Rest tremor	Restless leg syndrome
Inelasticity of muscles	Behaviour malady
	Daytime drowsiness
<b>Postural and gait damage:</b>	Episodic limb movement during sleep
Curved posture	<b>Sensory dysfunction:</b>
Reduction in arm swipe	Damage sense of smell
Damage Mobility and turning	Decline optical contrast and hue judgment
	Irregular sensation
	Pain

**Table 1:** Symptoms of Parkinson’s disease [1].

**\*Corresponding author:** Ayesha Malik, Department of Bioinformatics and technology, International Islamic University, Islamabad, Pakistan, Postal Code 44000, Tel: 9242111000010; E-mail: [ayesha.msbt226@iiu.edu.pk](mailto:ayesha.msbt226@iiu.edu.pk)

Received November 23, 2016; Accepted February 23, 2017; Published February 27, 2017

**Citation:** Malik A (2017) Gene Therapy of Parkinson’s Disease. J Mol Genet Med 11: 251 doi:10.4172/1747-0862.1000251

**Copyright:** © 2017 Malik A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Gene therapy approaches	Applications	References
Anti-apoptotic genes	Delivery of anti-apoptotic gene for the treatment of Alzheimer's disease.	[18]
Gene replacement	Lentiviral vectors expressing normal SMN1 gene in models of spinal muscular atrophy.	[19]
Knockdown of gene expression	Lentiviral vectors expressing siRNA targeted to mutant SOD1 gene in the model of amyotrophic lateral sclerosis.	[20]
Neurotrophic factors	Localized lentiviral mediated GDNF or DBNF delivery protects the surviving neurons from degradation in rodents' models of Parkinson disease.	[21-24]

**Table 3:** Some gene therapy approaches and their application in CNS disorders.

of most cancers, AIDS, cystic fibrosis, Parkinson's and Alzheimer's sicknesses, amyotrophic lateral sclerosis (Lou Gehrig's ailment), cardiovascular ailment and arthritis [13].

## Methods of Gene Delivery to Target Cells

### Non-viral methods

Various strategies are developed for transfer of gene to the target cells that embody infective agent vectors, and non-viral systems. Non-viral strategies that are marginally used for gene transfer to the central system (CNS), comprise chemical and physical strategies, like gene gun or electroporation. The power of infective agent vectors to convert nondividing cells is of crucial importance within the context of Parkinson's disease gene medical care [14].

Research efforts have yielded many non-viral strategies cistron transfer like electroporation (creation of electrical field iatrogenic openings in plasma membrane), sonoporation (ultrasonic rates to disturb cell membrane), magnetofection (usage of magnetic unit complexed with DNA), cistron guns (sprouts DNA covered gold units into cells by victimization high pressure) and receptor mediate cistron transfer area unit being explored. While every methodology has its own blessings and downsides [12].

### Viral methods

Viral vectors are built from wild-type viruses by eliminating the genes, crucial to their duplication, from their genome. The vectors are thus able to infect cells and transmission their genetic material into the nucleus, however they are not able to duplicate themselves within the host cells. This side is crucial for vector safety, because it removes virus pathogenicity and stops uncontrolled dispersal of transgene delivery initiated by vector replication within the host animal.

Here we are going to target vectors derived from adeno-associated virus (AAV) and lentivirus, as they're the sole ones that have touched the clinic for CNS cistron medical aid trials [14].

**Lentivectors:** Lentiviruses, belong to family *Retroviridae*. They are enveloped viruses whose genome contains single stranded RNA which encodes structural proteins. Their genome consists of four genes i.e. Gag, pol, tat, and rev. The highest packaging capability of lentivectors is eighteen kilo bases (KB), however the foremost economical packaging is attained with genomes within vary of half-dozen to nine KB [14].

**AAV-based vectors:** Aavs belongs of family *parvoviridae* family. They are small and non-enveloped viruses. Their genome size is 4.7 kb AAV which contains single-stranded DNA. This DNA encoding four proteins which are very vital for replication and packaging (*rep* gene), it also encodes three capsid proteins (*cap* gene) which are enclosed

by two inverted terminal repeats (ITR). AAV vectors are best vectors to transfer genes in the CNS. They provide us with very good safety profile, and effective transduction and strong expression of neurons. Beside all this there is also a limitation of AAV that is the restricted packaging volume (4.7 kb) that excludes the incorporation of huge genes [14].

## Discussion

### Effective gene therapy mediated products used for Parkinson's disease treatment

Parkin [15] GDNF (Glial cell line-derived neurotrophic factor) [16] and alpha synuclein [17] are the three-gene therapy based product of Parkinson's disease.

Glial cell line-derived neurotrophic factor (GDNF) ropes development and existence of dopaminergic (DA) neurons. Ad vector-mediated GDNF gene therapy might slough the DA neuronal cell harm in individuals with Parkinson's disease [17-24].

Parkin is gene product of familial Parkinson's disease. Viral vectors for Parkin manifestation have revealed neuro-protective properties in numerous animal models of Parkinson's disease [15].

## Conclusion

Parkinson's disease is a serious CNS disorder which need treatment on urgent basis as it has many symptoms which becomes worst with the passage of time (Table 3). Its prevalence is increasing and it has both genetic and sporadic factors involved. Symptomatic therapies show no effective treatment so researched move toward gene therapy. Production of novel vectors will increase the efficiency. Different product has been designed using gene therapy for the treatment of Parkinson's disease including Parkin, GDNF and alpha synuclein. But still there is need to further research in this field especially there is strong need to implement these Products on more Humans and design new vectors and products.

## References

- Massano J, Bhatia K (2012) Clinical approach to Parkinson's disease: Features, diagnosis, and principles of management. Cold Spring Harb Perspect Med 2(6): a008870.
- De Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neuro 5(6): 525-535.
- Twelves D, Perkins KS, Counsell C (2003) Systematic review of incidence studies of Parkinson's disease. Movement Disorders 18(1): 19-31.
- Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, et al. (2007) How common are the "common" neurologic disorders? Neurology 68(5): 326-337.
- Von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, et al. (2005) Prevalence and incidence of Parkinson's disease in Europe. European Neuropsychopharmacology 15(4): 473-490.
- Dorsey E, Constantinescu R, Thompson J, Biglan K, Holloway R, et al. (2006) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5): 384-386.
- Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. The Lancet Neurology 5(4): 355-363.
- Klein C, Westenberger A (2012) Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2(1): a008888.
- Miller A (1992) Human gene therapy comes of age. Nature 357(6378): 455-460.
- Verma IM, Weitzman MD (2005) Gene therapy: Twenty-first century medicine. Annu Rev Biochem 74: 711-738.

11. Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. *Nature Med* 7(1): 33-40.
12. Misra S (2013) Human gene therapy: A brief overview of the genetic revolution. *J Assoc Physicians India* 61(2): 127-133.
13. <https://www.ama-assn.org/ama/pub/physician-resources/medical-science/genetics-molecular-medicine/current-topics/gene-therapy.page?>
14. Coune P, Schneider B, Aebischer P (2012) Parkinson's disease: Gene therapies. *Cold Spring Harb Perspect Med* 2(4): a009431.
15. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. *Nat Genet* 25(3): 302-305.
16. Choi-Lundberg DL (2015) Dopaminergic neurons protected from degeneration by GDNF gene therapy 7: 838-841.
17. Maraganore DM (2015) Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. *JAMA* 296(6): 661-670.
18. Blömer U, Kafri T, Randolph-Moore L, Verma I, Gage F (1998) Bcl-xl protects adult septal cholinergic neurons from axotomized cell death. *Proc National Acad Sci* 95(5): 2603-2608.
19. Azzouz M, Le T, Ralph G, Walmsley L, Monani U, et al. (2004) Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. *J Clin Invest* 114(12): 1726-1731.
20. Raoul C, Abbas-Terki T, Bensadoun J, Guillot S, Haas G, et al. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. *Nature Medicine* 11(4): 423-428.
21. Déglon N, Tseng JL, Bensadoun JC, Zurn AD, Arsenijevic Y, et al. (2000) Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. *Hum Gene Ther* 11(1): 179-190.
22. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. *Science* 290(5492): 767-773.
23. Azzouz M, Ralph S, Wong LF, Day D, Askham Z, et al. (2004) Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector. *Neuroreport* 15(6): 985-990.
24. Kirik D, Georgievskaja B, Björklund A (2004) Localized striatal delivery of GDNF as a treatment for Parkinson disease. *Nature Neuroscience* 7(2): 105-110.